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ABSTRACT: 5-Hydroxymethylcytosine (5-hmC) is an enzy-
matic oxidative product of 5-methylcytosine (5-mC). The Ten
Eleven Translocation (TET) family of enzymes catalyze the
conversion of 5-mC to 5-hmC. Phage-encoded glucosyltrans-
ferases are known to glucosylate 5-hmC, which can be utilized
to detect and analyze the 5-hmC as an epigenetic mark in the
mammalian epigenome. Here we have performed a detailed
biochemical characterization and steady-state kinetic parameter
analysis of T4 phage β-glucosyltransferase (β-GT). Recom-
binant β-GT glucosylates 5-hmC DNA in a nonprocessive
manner, and binding to either 5-hmC DNA or uridine
diphosphoglucose (UDP-glucose) substrates is random, with both binary complexes being catalytically competent. Product
inhibition studies with β-GT demonstrated that UDP is a competitive inhibitor with respect to UDP-glucose and a mixed
inhibitor with respect to 5-hmC DNA. Similarly, the glucosylated-5-hmC (5-ghmC) DNA is a competitive inhibitor with respect
to 5-hmC DNA and mixed inhibitor with respect to UDP-glucose. 5-hmC DNA binds ∼10 fold stronger to the β-GT enzyme
when compared to its glucosylated product. The numbers of 5-hmC on target sequences influenced the turnover numbers for
recombinant β-GT. Furthermore, we have utilized recombinant β-GT to estimate global 5-hmC content in a variety of genomic
DNAs. Most of the genomic DNAs derived from vertebrate tissue and cell lines contained 5-hmC. DNA from mouse, human,
and bovine brains displayed 0.5−0.9% of the total nucleotides as 5-hmC, which was higher compared to the levels found in other
tissues. A comparison between cancer and healthy tissue genomes suggested a lower percentage of 5-hmC in cancer, which may
reflect the global hypomethylation of 5-mC observed during oncogenesis.
A
ddition of sugar residues by glycosidic bond formation
in living organisms is facilitated by large numbers of
glycosyltransferases. The glycosyltransferases utilize unique
cosubstrates, which are generally a sugar donor along with an
acceptor molecule with specific linkage specificity. One such
example of a glycosyltransferase is β-glucosyltransferase of the
Escherichia coli T4 bacteriophage. The β-GT transfers a glucose
residue from the cosubstrate UDP-glucose to the 5-hmC base,
as found in the T4 double-stranded DNA genome, converting it
to β-glucosyl-5-hydroxymethylcytosine. The role of glucosyla-
tion for T4 phage survival upon infection of a host E. coli
cell is well-documented.
1,2 Furthermore, glucosylation is also
implicated in phage specific gene expression by influencing
transcription.
3−5
Although 5-hmC is predominantly found in lower organisms,
such as T4 bacteriophage, it is also present in mammalian cells.
Earlier documentation of the tissue specific presence of 5-hmC
6
and the recent rediscovery of its presence in embryonic stem
cells (ESC)
7 and brain DNAs, especially in Purkinje neurons,
8
have generated interest. Although the biochemical pathways
of the oxidation of 5-methylcytosine (5-mC) to 5-hmC are
not completely understood, there is clear evidence of a family
of enzymes that mediate these reactions. The TET family
of enzymes (Tet1−Tet3) specifically bind 5-mC and catalyze
its conversion to 5-hmC.
7 Human Tet2 mutations are
associated with myeloid malignancies, perhaps because of
compromises in their catalytic activity, resulting in impaired
oxidation of 5-mC.
9
The role of 5-hmC in biology is not yet clear, but 5-hmC
has been postulated to influence chromatin structure, recruit
specific factors, or constitute an intermediate component in
cytosine demethylation. Indeed, oxidation of 5-mC by Tet1
promotes active DNA demethylation in the adult mammalian
brain. This process is aided by AID/APOBEC deaminase
followed by base excision repair processes.
10 Tet1 and Tet2 are
Oct4-regulated enzymes that together sustain 5-hmC levels in
mouse ESCs and are induced concomitantly with 5-hmC
during reprogramming of fibroblasts to induced pluripotent
stem cells.
11 In mouse ES cells, Tet1 is preferentially bound to
CpG-rich sequences at promoters of both transcriptionally
active and polycomb-repressed genes. Thus, Tet1 in mouse
ESC may have a dual function in gene activation and repress-
ion.
12 In human ESC, 5-hmC is present in gene bodies and
enhancer elements, and this presence correlates with gene ex-
pression.
13 Furthermore, recent studies have demonstrated that
reprogramming of the paternal genome upon fertilization in
mammals involves genome-wide oxidation of 5-mC to 5-hmC
and that the balance between these two DNA modifications is
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in mouse ESC.
14−16
Because 5-hmC has been implicated in stem cell biology and
cancer, several antibody-based immunoprecipitation methods
have been developed for genome-wide mapping and/or
quantification. In one of the approaches, termed GLIB
(glucosylation, periodate oxidation, biotinylation), a combina-
tion of β-GT and chemical steps is employed to isolate DNA
fragments containing as few as one 5-hmC.
17 The second approach
involves conversion of 5-hmC to cytosine 5-methylenesulfonate
(CMS) by treatment of genomic DNA with sodium bisulfite,
followed by immunoprecipitation of CMS-containing DNA
with a specific antiserum to CMS.
9 All these processes require
high-throughput sequencing to determine the 5-hmC mapping
on genes. Although antibody-based global 5-hmC level
quantification is possible, the linearity of the signal decreases
with higher DNA concentrations. Similarly, other global 5-hmC
level quantifications can be accomplished by high-performance
liquid chromatography (HPLC)−mass spectroscopy methods.
Recently, another study has used β-GT to measure global
5-hmC determination utilizing radioactive UDP-[3H]glucose,
18
thereby establishing β-GT as an important enzyme for
measuring global 5-hmC levels. Although high-resolution
crystal structures and the effects of substrate and metal binding
for β-GT were studied a decade ago, there is an apparent lack
of information about the basic biochemical parameters of
this enzyme. In this work, we have studied the biochemical
characterization and reaction mechanism of purified recombi-
nant β-GT (EC 2.4.1.27) from E. coli. This enzyme belongs to
glycosyltransferase family 63 (http://www.cazy.org/). Using the
optimal reaction conditions, we have further utilized a radioactive
labeling assay with β-GT to quantitatively measure 5-hmC levels
across many different tissue specific DNA samples, including
several novel sample types such as Arabidopsis and bovine.
■ EXPERIMENTAL PROCEDURES
Recombinant β-GT and MfeI Restriction Digest
Protection Assay. Recombinant β-GT was expressed in
E. coli, and the purified enzyme was obtained from New
England Biolabs, Inc. (NEB, catalog no. M0357S). For the MfeI
restriction digest protection assay, the glucosylation reactions
were conducted in 70 μL of NEB buffer 4 containing 0.188 nM
T4-gt DNA (the total concentration of 5-hmC residues was
∼11.2 μM), 50 μM UDP-glucose, and 30 nM β-GT. Aliquots
(10 μL) were withdrawn from the reaction mixture after
incubation for 0, 5, 10, 20, 30, 45, or 60 min at 37 °C. The
glucosylation reactions were stopped by heating each sample
for 20 min at 70 °C. After heat inactivation of β-GT, 1 μL
(10 units) of MfeI restriction endonuclease (NEB) was added
to each sample and each mixture incubated at 37 °C for 1 h to
cleave nonglucosylated T4-gt DNA. The restriction reaction
was quenched by adding 0.3 volume of gel loading buffer
[60 mM EDTA (pH 8.0), 50% glycerol, 0.2% SDS, and 0.02%
bromophenol blue], and the products were separated by
electrophoresis in a 1% agarose gel. The ethidium bromide-
stained gel was visualized under UV light.
Glucosylation Assay for 5-hmC DNA. UDP-[1-3H]-
glucose (UDP-[3H]glucose, American Radiolabeled Chemical,
Inc., catalog no. ART 0525) was diluted with cold UDP-glucose
(NEB) to form a 0.225 mM stock solution. A standard gluco-
sylation assay for 5-hmC quantification consisted of a fixed
concentration of UDP-[3H]glucose and a known quantity of
purified mutant T4-gt DNA (NEB), where all cytosine residues
are modified 5-hmC (mutations in both α and β-GT), and they
were mixed with different concentrations of recombinant β-GT
in 1× NEB buffer 4 [50 mM potassium acetate, 20 mM Tris
acetate, 10 mM magnesium acetate, and 1 mM DTT (pH 7.9)]
at 25 °C. Reaction mixtures were incubated at 25 °C for various
time intervals, and 25 μL of each reaction mixture was mixed
with 5 μL of 400 μM cold UDP-glucose and flash-frozen on
ethanol and dry ice for processing. The reaction mixtures were
thawed and immediately applied to a 2.5 cm DE81 membrane
(GE Healthcare, catalog no. 3658-325) under air pressure using
a vacuum manifold (Millipore). The applied reaction mixture
was washed in 3 × 1 mL of 0.2 M ammonium bicarbonate,
3 × 1 mL of water, and 3 × 1 mL of ethanol. Membranes
were air-dried and placed in scintillation vials. To the dried
filter was added 3 mL of scintillation fluid; the solution was
mixed, and tritium incorporation was measured for 1 min.
All glucosylation reaction values were corrected for nonspecific
binding of UDP-[3H]glucose to the processed filters. Background
values were determined in the absence of enzyme or substrate but
i nt h ep r e s e n c eo fU D P - [ 3H]glucose in the reaction mixture.
The counting efficiency of incorporation of [3H]glucose was
determined to be ∼50% by using internal standards. Therefore,
during all our calculations, a correction value of 2 was included.
Data were plotted by either linear or nonlinear regression analysis
using GraphPad PRISM 4 (GraphPad Software, Inc.).
DNA Substrate for the 5-hmC Assay. T4-gt DNA was
obtained from NEB. Duplex DNA substrates containing 2, 6,
12, or 24 residues of 5-hmC were made by polymerase chain
reaction (PCR) in the presence of d(5-hm)CTP nucleoside in
place of 5-dCTP using Phusion high-fidelity DNA polymerase
(NEB, catalog no. M0530S). The sequences of the synthesized
duplex DNAs are as follows:
13 2 × 5-hmC-DNA, 5′ TACT-
CTATACTCTACTCATCATTACAATATATATATAAT-
TAATTATAATTAACGAAATTATAATTTATAATTAAT-
TAATATGAGATATGAGATGTGTATG 3′;6× 5-hmC-DNA,
5′ TACTCTATACTCTACTCATCATTACAATATATATA-
TAATTAATTATAATTCGCGAAATTACGATTTATAAT-
TAATTAATATGAGATATGAGATGTGTATG 3′;1 2× 5-hmC
DNA, 5′ TACTCTATACTCTACTCATCATTACAATATATA-
TATCGTTAACGATAATTCGCGCGATTACGATTTA-
TAATTAATTAATATGAGATATGAGATGTGTATG 3′;2 4×
5-hmC DNA, 5′ TACTCTATACTCTACTCATCATTACA-
CGCGCGATATCGTTAACGATAATTCGCGCGATTAC-
GATCGATAACGCGTTAATATGAGATATGAGATGTG-
TATG 3′. PCR products were biotinylated by virtue of using
5′-biotinylated PCR primers in a standard PCR with Phusion high-
fidelity DNA polymerase (NEB). All hydroxymethyl CpG dinu-
cleotides are shown in bold.
The double-stranded hemi-5-hydroxymethylated and sym-
metrical 5-hydroxymethylated synthetic oligonucleotides, synthe-
sized at NEB, were utilized as 5-hmC substrates. Oligonucleotide
pairs were annealed in 10 mM Tris (pH 8.0), 50 mM NaCl, and
1 mM EDTA. The sequences for the double-stranded synthetic
oligonucleotides were as follows, with the hydroxymethylated
cytosines shown in bold type: hemi-5-hmC (A), 5′ CGGC-
GTTTCCGGGTTCCATAGGCTCCGCCCGGACTCTGAT-
GACCAGGGCATCACA 3′ and 3′ GCCGCAAAGGCC-
CAAGGTATCCGAGGCGGGCCTGAGAC-
TACTGGTCCCGTAGTGT 5′;h e m i - 5 - h m C( B), 5′ CGGC-
GTTTCCGGGTTCCATAGGCTCCGCCCGGACTCTGAT-
GACCAGGGCATCACA 3′ and 3′ GCCGCAAAGGCC-
CAAGGTATCCGAGGCGGGC CTGAGAC-
TACTGGTCCCGTAGTGT 5′; symmetrical 5-hmC (C),
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GACTCTGATGACCAGGGCATCACA 3′ and 3′ GCCGCA-
AAGGCCCAAGGTATCCGAGGCGGGCCTGAGAC-
TACTGGTCCCGTAGTGT 5′.
Processivity Studies with Recombinant β-GT. For
processivity studies, a master mix (300 μL) of 1.35 μM
biotinylated DNA that contained 24 5-hmC residues (24 ×
5-hmC), 50 μM UDP-[3H]glucose, and 0.01 μM recombinant
β-GT was incubated on ice for 3 min. At that point, the
reaction mixture was brought to room temperature and divided
into two samples. A 12-fold excess of nonbiotinylated 24 ×
5-hmC was added to one of the samples and the sample mixed.
To the other sample was added an equal volume of water. After
incubation for 1 min at 25 °C, 25 μL of reaction mixture was
removed from both samples, at intervals of 30 s, and mixed with
5 μL of 400 μM cold UDP-glucose and flash-frozen on ethanol
and dry ice for processing.
Initial Velocity and Product Inhibition Studies with
Recombinant β-GT. All initial velocity studies were conducted
under identical conditions as described in Glucosylation Assay
for 5-hmC DNA. For initial velocity studies with 5-hmC
containing substrate DNA, the concentration of 5-hmC was
varied (0.03−1.0 μM) while the UDP-glucose and β-GT
concentrations were kept at 2.5 and 0.01 μM, respectively, in
the incubation mix. Similarly, for initial velocity studies with the
UDP-glucose substrate, the concentration of UDP-glucose was
varied (2.5−50.0 μM), while the 5-hmC DNA and β-GT
concentrations were kept at 0.025 and 0.01 μM, respectively, in
the incubation mix. The amount of product formed was
measured in counts per minute. The concentration of product
formed ([3H]glucose transfer, N) was calculated using the
formula N =( Y − B)/(EF), where Y is the measured counts per
minute from the experiment, B is the counts per minute blank,
E is the counting efficiency (0.5), and F is the counts per
minute per micromolar free UDP-[3H]glucose. The amount of
product formed per minute is measured as N/T, where T is the
time of the reaction. The initial rate of product formation
versus substrate concentration was fit to a one-site binding
model (hyperbola). The velocity equation in the absence of
product is as follows.
=+ v VK ( [S])/( [S]) max m (1)
where [S] is [UDP-glucose][5-hmC]. This describes binding of
a substrate or ligand to an enzyme that follows the law of mass
action. Vmax is the maximal velocity, and Km is the concentration
of substrate needed to reach the half-maximal velocity. All data
points were analyzed by nonlinear regression to yield Vmax and
Km. From the Vmax value, the turnover number (kcat) was
deduced from the known enzyme concentration, where Et is
the enzyme concentration.
= kV /[Et] cat max
Initial velocity studies in the presence of either of the
products were performed to deduce the reaction mechanism of
recombinant β-GT. The enzyme has two products in the
reaction, UDP and 5-ghmC. The UDP (Sigma, catalog no.
U4125) solution was made in Milli-Q water at 100 μM. For
glucosylated DNA, wild-type T4 DNA (T4-wt) (NEB) was
used. The difference between T4-gt and T4-wt was the fact that
all the cytosine residues in T4-gt are 5-hydroxymethylcytosine.
To perform the product inhibition reactions, a series of reactions
were performed with fixed amounts of end product. In the
experiment with UDP as the end product, the concentrations of
reactants were as follows: 2.5 μM 5-hmC, 2−40 μM UDP, and
2.5−50 μM UDP-[3H]glucose or 0.03−1.0 μM 5-hmC, 25 μM
UDP, and 2.5−50 μM UDP-[3H]glucose. Similarly, in the
experiment with 5-ghmC as the end product, the concentra-
tions of reactants were 0.125−7.2 μM for 5-hmC and 2.5−
50 μM for UDP-[3H]glucose. The data obtained from inhibi-
tion studies were fit to equations stipulated for competitive or
mixed inhibition as described previously.
19
Global 5-hmC Quantification in Mammalian Genomes
by a Glucosylation Assay. Genomic DNA samples from
E14, COS-7, control ES (E14), Tet1 KD ES (E14 Tet1−/−),
U 3 8 7 ,N I H - 3 T 3 ,H E K 2 9 3 ,H C T1 1 6W T ,H C T1 1 6
(DNMT1−/−), E14 day 1, E14 day 3, E14 day 5, E14 day 7,
HeLa, and IMR 90 cells were purified with Qiagen Puregene
Core Kit A (catalog no. 1042601). Genomic DNA samples
were treated with Qiagen RNase A (catalog no. 19101) to
remove RNA contamination. Genomic DNA tissue samples
from mouse brain, liver, kidney, heart, and lung were purchased
from BioChain. These genomic DNA samples were treated
with Agilent Technologies RNace (RNase A and RNase T1,
catalog no. 400720) to ensure samples were RNA free. For the
β-GT glucosylation assay, 1 μg of purified DNA was incubated
with 25 μM UDP-[3H]glucose (125 μM stock) and 5 units of
β-GT enzyme in a total volume of 25 μL. The β-GT and
reaction mixtures were incubated at 37 °C for 2 h. The reaction
mixtures were then applied to DE81 membranes and processed
as described above.
The femtomole readings were converted to % 5-hmC and %
modified cytosines in the genome with the following equation:
‐
=‐
total % 5 hmC in genome
(moles of 5 hmC measured)
/[(grams of DNA measured)/(MW of DNA base)]
■ RESULTS
Preliminary Characterization of Recombinant β-GT.
Commercially available recombinant β-GT was homogeneous
with a single band on a Coomassie-stained sodium dodecyl
sulfate−polyacrylamide gel electrophoresis (SDS−PAGE) gel
(Figure 1A). The enzyme was tested for glucosylation activity
on 5-hmC containing T4 phage DNA (T4-gt DNA). Initially,
we developed a restriction enzyme-based assay method in
which T4-gt DNA was resistant to cleavage by MfeI after the
glucosylation reaction. Judging by the resistance to cleavage by
MfeI as a function of recombinant β-GT-mediated catalysis
over time, we determined that the 30 nM enzyme is highly
efficient in glucosylating 0.188 nM T4-gt DNA in 10 min of the
reaction (Figure 1B). This result suggested the linear phase of a
β-GT reaction to be less than 10 min.
Linearity of the Glucosylation Reaction by Recombi-
nant β-GT Using UDP-[3H]Glucose. To determine the linear
reaction phase of recombinant β-GT, we added a fixed
concentration of β-GT and a fixed concentration of DNA
with four different concentrations of cosubstrate UDP-glucose.
From the reaction mixture, 25 μL was withdrawn at 1 min time
intervals for quantitative estimation of glucosylation. At all
four different concentrations of UDP-glucose (5, 10, 25, and
50 μM), the reaction essentially remained linear up to 5 min
(Figure 2A). We also conducted another set of experiments by
Biochemistry Article
dx.doi.org/10.1021/bi2014739 | Biochemistry 2012, 51, 1009−1019 1011varying the recombinant β-GT concentration and keeping
the DNA concentrations fixed with two different UDP-glucose
concentrations (5 and 25 μM). Indeed, the glucosylation
reaction remained virtually linear with enzyme concentration
between 0.0025 and 0.02 μM (Figure 2B). From these data, we
chose an optimal enzyme concentration to be 0.01 μM in our
reactions and the optimal reaction time to be 2 min at 25 °C.
β-GT Glucosylates 5-hmC in a Distributive Manner.
5-Hydroxymethylcytosine is capable of accepting one glucose
group from UDP-glucose by β-GT. This reaction could happen
in a processive or distributive manner. To determine the
reaction process, we incubated the biotin-tagged 5-hmC
containing DNA in the presence of a limiting amount of
β-GT and excess UDP-[3H]glucose. We preincubated this
reaction on ice for 3 min to promote ternary complex
formation. This reaction mix was split into two equal portions,
and to one half was added 12-fold competitor DNA containing
5-hmC but without a biotin tag. After incubation for 1 min
at 25 °C, duplicate aliquots were collected every 30 s and
quenched. The biotinylated substrates were captured with
streptavidin beads, and radioactive incorporation was measured.
In the event of a processive mechanism, the enzyme would
remain bound to the biotinylated substrate and would not be
released to the competitor until all the available 5-hmCs are
glycosylated. In a distributive mechanism, the enzyme is
expected to fall off the substrate after one catalytic reaction
and then use the available pool of substrates for the next
reaction. Because the enzyme-loaded substrate is biotinylated,
the amount of products in the presence and absence of
competitor DNA could be captured by streptavidin magnetic
beads. Should the enzyme be released from the biotinylated
DNA to competitor DNA, the biotinylated DNA will not be
glucosylated. Indeed, in the presence of competitor DNA, β-GT
failed to glucosylate the preloaded substrate DNA (Figure 3),
as the reaction curve remained parallel to the x-axis. The
control reaction showed a linear reaction progression. There-
fore, β-GT appears to follow a distributive mechanism of
reaction.
Initial Velocity Studies with Variable UDP-Glucose
and 5-hmC DNA. Initial velocity experiments allow the
Figure 2. Linearity of glucosylation by recombinant β-GT. (A) Linearity of glucosylase reaction as a function of time with four different
concentrations of UDP-[3H]glucose: 50 (◇), 25 (▼), 10 (△), and 5 μM( ■). All reaction mixtures contained 0.01 μM β-GT and 2.5 μM 5-hmC
and were incubated at 25 °C. Twenty-five microliters of the reaction mixture was spotted on DE81 at 1 min time intervals and processed as
described in Experimental Procedures. (B) Linearity of the glucosylase reaction as a function of recombinant β-GT enzyme concentration (0.00025−
0.02 μM) with 50 (△)o r2 5μM UDP-[3H]glucose (■). Twenty-five microliters of the reaction mixture was spotted on DE81 after incubation with
the appropriate concentration of the β-GT enzyme for 2 min.
Figure 3. Nonprocessive glucosylation catalyzed by recombinant
β-GT. Incorporation of UDP-[3H]glucose after the enzyme was
preincubated on ice with 50 μM UDP-[3H]glucose and 1.35 μM
5-hmC DNA. Three minutes after the start of the reaction the mixture
was divided into two equal portions, one chased with nonbiotinylated
5-hmC DNA (▼) and the other with an equal volume of water (○)a s
described in Experimental Procedures. After the chase, both reaction
mixtures were incubated at (25 °C) for 1 min and then monitored at
30 s intervals by processing 25 μL of the reaction mixture in duplicate.
Measurements were obtained from streptavidin magnetic beads with
captured glucosylated [3H]-5-hmC.
Figure 1. Purity and initial characterization of the β-GT enzyme. (A)
Coomassie blue-stained SDS−PAGE gel showing 8 μg (80 units) of
recombinant β-GT enzyme. (B) Glucosylation of 5-hmC DNA (T4
phage gt −/− DNA) with recombinant β-GT protects it from cleavage
by MfeI. A time course of the glucosylation reaction followed by MfeI
digestion is shown. The arrow indicates T4 phage gt −/− DNA.
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substrate, which in turn establish parameters for the kinetic
mechanism of a reaction. In the case of recombinant β-GT,
there are two different substrates, UDP-glucose and 5-hmC
DNA. To determine the kinetic constants, we varied the UDP-
glucose concentration from 0 to 50 μM, keeping the 5-hmC
DNA in excess (2.5 μM) and recombinant β-GT at 0.01 μM.
Similarly, for determination of 5-hmC DNA kinetic parameters,
we varied the 5-hmC DNA concentration between 0 and
7.5 μM and kept the UDP-glucose in excess (50 μM) and the
enzyme concentration at 0.01 μM. We plotted glucosylation
as a function of UDP-glucose (Figure 4A) or 5-hmC DNA
(Figure 4B). The apparent Km
5‑hmC and Km
UDP‑glucose values
were 0.41 and 16 μM, respectively (Table 1). The turnover
number for β-GT on T4-gt DNA was 77 min−1 (Table 1).
Product Inhibition Studies of Recombinant β-GT with
UDP and 5-ghmC DNA. To provide insight into the reaction
mechanisms, we conducted product inhibition studies. An
equilibrium scheme for enzyme turnover in the presence or
absence of the product is shown in Figure 5A. Because of the
structural similarities between substrate UDP-glucose and
UDP, 5-hmC, and 5-ghmC DNAs, the product molecule of
an enzymatic reaction is expected to be competitive with the
original substrate molecule. The product molecule may bind
directly at the active site, blocking further binding of the
substrate molecule, or it can bind at the proximity of the
active site and influence structural constraints for substrate
binding. In a bisubstrate reaction, as in the case of recombinant
β-GT, the calculated inhibition constants are apparent, for
the given concentration of the cosubstrate, which is fixed.
For glucosyltransferases such as β-GT, transfer of glucose from
UDP-glucose to 5-hmC DNA generates two different products,
UDP and 5-ghmC. Because β-GT is a bisubstrate enzyme,
a competitive inhibitor of one of the substrate-binding sites
will display either a competitive or a mixed inhibition pattern,
depending on which substrate binds first to the enzyme.
Varying the amounts of UDP-glucose with different fixed
amounts of UDP yielded a set of double-reciprocal plots that
converged on the y-axis intercept (Figure 5B), suggesting UDP
is a competitive inhibitor with respect to UDP-glucose.
Nonlinear regression analysis of the same series of reactions
displayed similar Vmax values but different Km
app values (data
not shown). The Ki value of UDP was ∼9 μM (Table 1) and
was calculated by plotting Km
app versus inhibitor concentration
(see the inset of Figure 5B). The Ki value for UDP is 2-fold
lower than the Km value for UDP-glucose (Table 1), suggesting
a higher affinity for UDP by the β-GT enzyme. Varying the
amounts of 5-hmC DNA with different fixed concentrations of
UDP resulted in a set of reciprocal plots that all converged to
the left of the y-axis (Figure 5C), indicating that UDP acts as a
mixed inhibitor with respect to 5-hmC DNA.
Similarly, varying levels of 5-hmC DNA with different fixed
amounts of 5-ghmC DNA yielded a set of double-reciprocal
plots that did converge on the y-axis (Figure 5D), revealing that
5-ghmC acts as a competitive inhibitor with respect to 5-hmC.
The Ki value of 5-ghmC was ∼4 μM (Table 2). The Ki value
for 5-ghmC is 10-fold lower than the Km value for 5-hmC
(Tables 1 and 2), suggesting a much higher affinity of the β-GT
enzyme for 5-hmC. Varying amounts of UDP-glucose with different
fixed concentrations of 5-ghmC resulted in a set of reciprocal
Figure 4. Substrate−velocity curves of recombinant β-GT. (A) Recombinant β-GT activity with UDP-[3H]glucose substrate. Glucosylation reactions
were conducted at UDP-[3H]glucose substrate concentrations of 0, 2.5, 5, 10, 25, and 50 μM and fixed enzyme and 5-hmC DNA concentrations of
0.01 and 2.5 μM, respectively. Product formation is plotted vs substrate concentration, and nonlinear regression was performed to determine
Km
UDP‑glucose values. (B) Recombinant β-GT activity with a 5-hmC DNA substrate. Glucosylation reactions were conducted with 5-hmC DNA
substrate concentrations of 0, 0.125, 0.25, 0.5, 1, 3.6, and 7.2 μM and fixed enzyme and UDP-[3H]glucose concentrations of 0.01 and 50 μM,
respectively. Product formation is plotted vs substrate concentration, and nonlinear regression was performed to determine Km
5‑hmC values.
Table 1. Steady-State Kinetic Parameters of Recombinant β-GT
a
substrate Km
5‑hmC (μM) Km
UDP‑glucose (μM) kcat/Km
5‑hmC (μM min−1) kcat
5‑hmC (×106 M −1 min −1)
T4-gt DNA 0.4 ± 0.1 16 ± 3 192 77
2 × 5-hmC DNA 3 ± 0.6 NA 56 168
6 × 5-hmC DNA 0.6 ± 0.1 NA 166 100
12 × 5-hmC DNA 0.23 ± 0.06 NA 269 62
24 × 5-hmC DNA 0.22 ± 0.05 NA 264 58
aThe T4-gt DNA substrate has every cytosine hydroxymethylated. The 2 to 24 × hmC DNA substrates are 100 bp double-stranded PCR products
containing a number of hmC residues equivalent to their identifiers. All tested samples were assessed in duplicate (±standard deviation). See
Experimental Procedures for sequences of 100 bp fragments.
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inhibition pattern (Figure 5E). The αKi values were obtained
by plotting 1/ Vmax versus inhibitor concentration (data not
shown). The Ki and αKi for UDP and 5-hmC DNA were 2 and
72 μM, respectively. Similarly, the Ki and αKi for 5-ghmC DNA
and UDP-glucose were 3 and 5 μM, respectively (Table 2).
Differential Glucosylation by Recombinant β-GT on
5-hmC-Containing Substrates. Because β-GT is a T4
phage-encoded enzyme in which most of the 5-hmC is
c o n v e r t e dt og l u c o s y l a t e d5 - h m C ,w ed e t e r m i n e di fa n
increased density of 5-hmC on a specific sequence of DNA
can affect the steady-state kinetic parameters of the enzyme. We
amplified via PCR DNAs with 2, 6, 12, or 24 × 5-hmC sites and
used them as substrates. The enzyme bound strongly to DNA
containing larger numbers of 5-hmC residues (>12) as
Figure 5. Reaction mechanism of recombinant β-GT and double-reciprocal plots of the initial velocity vs substrate concentration. (A) Scheme
detailing the turnover of recombinant β-GT enzyme in the presence or absence of product inhibitors. The substrate 5-hmC or UDP-glucose is S.
The product glucosylated 5-hmC is I. The inhibitor constant is Ki. The binary inhibitor constant is αKi. The degree of modification the first substrate
exerts on binding of the second substrate is α. (B) Double-reciprocal plots for fixed 5-hmC substrate and variable UDP concentrations of 0 (■),
2( ○), 8 (◆), 12 (△), and 16 μM( ▼). Linear regression was performed, and 1/v was plotted vs 1/[UDP-[3H]glucose]. The inset replot of
Km
UDP‑glucose vs UDP was used to calculate the Ki value of UDP as a competitive inhibitor with respect to the formation of a β-GT−UDP-glucose
complex. (C) Double-reciprocal plots for fixed UDP-[3H]glucose substrate and variable UDP concentrations of 0 (■), 20 (△), 30 (▼), and 40 μM
(◊). Linear regression was performed, and 1/v was plotted vs 1/[5-hmC]. The inset replot of slope vs UDP was used to calculate the αKi of UDP as
a mixed inhibitor with respect to the formation of a β-GT−5-hmC complex. (D) Double-reciprocal plots for fixed UDP-[3H]glucose substrate and
variable glucosylated 5-hmC concentrations of 0 (■), 1 (△), 2.5 (▼), and 5 (○). Linear regression was performed, and 1/v was plotted vs 1/[5-
hmC DNA]. The inset replot of Km
5‑hmC vs 5-ghmC was utilized to calculate the Ki value of 5-ghmC as a competitive inhibitor with respect to the
formation of a β-GT−5-hmC complex. (E) Double-reciprocal plots for 5-hmC concentration and variable glucosylated 5-hmC concentrations of
0( ○), 1 (■), 2.5 (▽), and 5 μM( ◆). Linear regression was performed, and 1/v was plotted vs 1/[UDP-[3H]glucose]. The inset replot of slope vs
5-ghmC was used to calculate the αKi of 5-ghmC as a mixed inhibitor with respect to formation of a β-GT−UDP-glucose complex.
Table 2. Product Inhibition Pattern of Recombinant β-GT
a
product
variable
substrate fixed substrate
type of
inhibition
Ki
(μM)
αKi
(μM)
UDP UDP-glucose 5-hmC competitive 9
UDP 5-hmC UDP-glucose mixed 2 72
5-ghmC 5-hmC UDP-glucose competitive 4
5-ghmC UDP-glucose 5-hmC mixed 3 5
aThe DNAs used for the assay were 5-hmC DNA (T4-gt DNA) and
5-ghmC DNA (T4-wt DNA) and tested in duplicate (±standard
deviation).
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Stronger binding also influenced the reaction velocity, resulting
in lower turnover numbers. For example, the DNA samples
described above with 2, 6, 12, and 24 × 5-hmC displayed turnover
numbers of 168, 100, 62, and 58, respectively (Table 1).
In another assay, we studied the kinetic parameters of
recombinant β-GT on hemihydroxymethylated versus fully
hydroxymethylated symmetrical CG sequence. Once again, the
symmetrical 5-hmC-containing oligonucleotide duplex dis-
played a higher turnover number, 310, than the hemi-5hmC
corresponding sequences, which exhibited numbers of 8 and 5
(Table 3). Previous studies that have utilized β-GT to measure
the levels of 5-hmC have not observed β-GT’ss t r o n g
preference for the glucosylation of symmetrical 5-hmC over
hemi-5-hmC. When the oligonucleotide duplexes at identical
molarities of 5-hmC were again incubated with β-GT, but this
time for a longer period of time (2 h), this revealed that β-GT
is capable of saturation glucosylation on all conformations of
5-hmC (Figure 6B). From the experiments described above, we
conclude that the numbers of 5-hmC residues on DNA can
influence β-GT catalysis, especially the rate of catalysis, and
hemihydroxymethylated DNA is not the preferred substrate of
the enzyme.
Determination of Global 5-hmC Levels in Various
Genomes by Glucosylation. Because β-GT-mediated trans-
fer of a tritiated glucose molecule is efficient, we extended our
studies to global genomic 5-hmC quantification by [3H]glucose
incorporation. First, to determine if the transfer of [3H]glucose
to hydroxymethylated cytosine is linear with regard to total
5-hmC content, a 100 bp double-stranded PCR fragment
containing 24 × 5-hmC was utilized as a standard substrate for
the β-GT enzyme. Unlike our previous glucosylase reactions,
which characterized the β-GT enzyme, these assays were
conducted for 2 h at 37 °C to ensure complete glucosylation of
all 5-hmC residues. The glucosylation reaction was strictly
linear (r = 0.9997) within the range of 12−500 fmol of
standards when cold UDP-glucose was used in a 4-fold excess
over UDP-[3H]glucose (Figure 7A). Furthermore, at least 92%
of the total 5-hmC in these standards was labeled with UDP-
[3H]glucose, revealing that these conditions allowed for the
sensitive and accurate measurement of total 5-hmC content.
The 5-hmC levels ranged from 2 to 30 fmol of 5-hmC/μg
of genomic DNA tested, corresponding to the percentage
coverage values listed in Table 4. This revealed that the highest
percentages of 5-hmC tested were in the human, mouse, and
cow brain tissue samples (0.5, 0.9, and 0.7% of total
nucleotides, respectively). The 0.9% of global 5-hmC that we
recorded in mouse brain tissue was only slightly lower than
the ∼1.1−1.5% of 5-hmC recorded by Szwagierczak et al. in
different types of mouse brain tissues.
18 Furthermore, another
report using thin layer chromatography and high-pressure
liquid chromatography coupled to mass spectrometry had very
similar results, quantifying global 5-hmC levels in Purkinje
tissue to be 0.6%,
8 which was similar to the value of 0.5% that
we measured in the human brain tissue sample using our
experimental protocol.
Plants utilize a DEMETER class of DNA glucosylases to tar-
get and remove 5-mC from their genomes.
20,21 This negates
the need for plants to have a Tet1 homologue to convert 5-mC
into the 5-hmC intermediate required to possibly promote DNA
demethylation. Furthermore, there are no known homologues of
Figure 6. Glucosylation of different 5-hmC-containing substrates by recombinant β-GT. (A) Recombinant β-GT activity with 100 bp double-
stranded DNA substrates containing 2 (●), 6 (△), 12 (■), or 24 cytosines (○) that are hydroxymethylated. Glucosylation reactions were performed
at 5-hmC concentrations of 0, 0.125, 0.25, 0.5, 1, and 2.5 μM and fixed enzyme and UDP-[3H]glucose concentrations of 0.01 and 50 μM,
respectively, in a total volume of 25 μL. (B) End point analysis of recombinant β-GT activity with 55 bp double-stranded substrates containing hemi-
5-hmC pair A, hemi-5-hmC pair B, or symmetrical 5-hmC. Glucosylation reactions were performed with 1 μM 5-hmC, 50 μM UDP-[3H]glucose,
and 5 units of recombinant β-GT in a 25 μL reaction mixture for 2 h. The reaction mixture was spotted in duplicate on DE81 membranes, and
glucosyl group incorporation was measured.
Table 3. Hemi versus Symmetrical 5-hmC as a Substrate for
Recombinant β-GT
a
substrate Km
5‑hmC
kcat/Km
5‑hmC
(μM min−1)
kcat
5‑hmC
(×106 M −1 min−1)
hemi-5-hmC (A) 0.4 ± 0.1 20 8
hemi-5-hmC (B) 0.2 ± 0.1 25 5
symmetrical
5-hmC
2.0 ± 0.5 155 310
aHemi-5-hmC (A and B) and symmetrical 5-hmC are 55 bp double-
stranded synthetic oligonucleotides containing either a single hemi-5-
hmC or two symmetrical 5-hmC residues. All tested samples were
assessed in duplicate (±standard deviation). See Experimental
Procedures for sequences of 55 bp fragments.
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with these findings, the plant genomes tested displayed low levels
of 5-hmC (<0.07% of the total nucleotides). Similarly, sea urchin
(Lytechinus variegatus) embryos had small amounts of genomic
5-hmC at early and mid gastrula (<0.07% of total nucleotides),
although there was an increase in the level of 5-hmC (0.11%) 36
hours post fertilization. Analysis of cancer and matched tissue
genomes showed reduced amounts of 5-hmC (Figure 7B). For
example, normal lung, breast, and colon versus cancer genomes
were 0.15% versus 0.08%, 0.16% versus 0.07%, and 0.20% versus
0.09% of total nucleotides, respectively (Table 4). In the colorectal
cancer cell line HCT116, the level of 5-hmC was 0.12%, a value
reduced to 0.07% in DNMT1 null cells in a HCT116 cell
background, which was hypomethylated for 5-mC. Similarly, wild-
type mouse ESC displayed 0.27% 5-hmC as compared to 0.22% in
Tet1 null ES cells, suggesting a loss of Tet1 function reduces the
level of 5-hmC in the genome.
■ DISCUSSION
Modified DNA bases are widespread in living organisms from
viruses to mammals. In T4 phages, most of the cytosine
residues are present as 5-hydroxymethylcytosine and are often
completely glucosylated by virally encoded β-GT.
2,22 Similarly,
in the mammalian genome, a percentage of cytosine residues
are 5-mC, and a percentage of that is further oxidized to
5-hmC. In 1972, formic acid hydrolysis followed by chromato-
graphic analysis was used to detect 5-hmC in murine brain and
liver DNA. Using this method, 5-hmC was estimated to
comprise ∼15% of the total cytosine residues.
23 Recently, β-GT
was used in combination with a radioactive UDP-glucose
to determine global 5-hmC levels. In our previous report,
we successfully utilized a glucosylation step using a
recombinant β-GT in combination with restriction enzyme
cleavage to quantify the percentage of C, 5-mC, and 5-hmC in
mammalian genomes.
24 To understand the detailed biochem-
ical properties of recombinant β-GT, we determined a series of
steady-state kinetic properties and the reaction mechanisms of
the enzyme.
Recombinant β-GT glucosylates double-stranded 5-hmC
DNA very efficiently, as shown by its ability to completely
glucosylate ∼100-nucleotide substrates and T4-gt DNA when
the enzyme is given sufficient time. However, clusters of six or
more 5-hmC residues on the 100 bp duplex substrate led to
reduced turnover numbers and Km values, indicating that β-GT
binds tightly to clustered 5-hmC on DNA. Such behavior
stands in contrast to that of other transferases such as DNA
methyltransferase 3A (Dnmt3A), where increases in the density
of methylation target sites resulted in higher rates of DNA
methylation.
25 Crystallographic studies of β-GT were not able
to distinguish between a processive or distributive mode of
glucosylation between adjacent 5-hmC residues. A processive
mechanism seems unlikely because the active site of the β-GT
is completely closed upon substrate DNA binding, requiring
unfolding after catalysis to release the UDP product and bind
new UDP-glucose substrate.
26,27 This hypothesis was exper-
imentally confirmed in our studies, as the chase nonbiotinylated
substrate was able to remove the enzyme and UDP-glucose
from the prebound biotinylated substrate DNA. This reaction
mechanism was confirmed by product inhibition studies in
which β-GT appears to follow a bi-bi random reaction
mechanism. Similar reaction mechanisms are common for
other histone and DNA methyltransferases, such as lysine
methyltransferases (G9a
28 and SUV39H
19) and DNA cytosine
5-methyltransferases (DNMT1,
29 M.HhaI,
30 and M.BamH1
31).
However, in vivo, most of the enzymes may reside in
complexes, and the reaction pathways and product formation
may be different.
Cell culture-based studies have identified a strong correlation
between DNA hypomethylation (reduction of 5-mC) and
tumorigenesis.
32,33 In a recent study, 5-mC was purposely
converted to 5-hmC in adult mouse brain, and this promoted
demethylation through a process requiring base excision repair.
Furthermore, the 5-hmC is actively removed by the activation-
induced deaminase/APOBEC family of cytidine deaminases in
mammalian cells.
10 This evidence would indicate that late stage
tumorigenic samples should have lower levels of 5-hmC, when
compared to match normal tissue, because 5-hmC is the
precursor to the hypomethylation. To test this hypothesis, we
measured 5-hmC levels in matched pairs of human genomic
DNA from brain, lung, breast, colon, and liver tissues that were
Figure 7. Global 5-hmC levels determined in the genomes of various tissues, and corresponding tumor samples, by recombinant β-GT. (A)
Calibration curve using different amounts of 0, 0.5, 1, 2, 5, 10, and 20 μM 5-hmC with 5 units of recombinant β-GT and 25 μM UDP-[3H]glucose in
a total reaction volume of 25 μL. The reaction mixture was spotted in duplicate on DE81 membranes, and glucosyl group incorporation was
measured. The linear relationship between [3H]glucose incorporation and the molarity of 5-hmC is 0.9997. (B) Glucosylation is utilized to measure
global 5-hmC levels in matched normal and tumor genomic DNA samples, as described in Experimental Procedures. Note that all tumor samples
have significantly lower levels of 5-hmC when compared to the matched normal sample (p < 0.001).
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had significantly (p < 0.001) lower levels of genomic 5-hmC
than their matched normal tissue (Figure 7B). This evidence
lends credibility to the possibility that 5-hmC is acting as a
precursor to hypomethylation or 5-hmC reductions are a
reflection of reduced precursor 5-mC. Indeed, 5-mC levels in
a large series of tumor DNA samples are significantly lower
than what was observed in their matched normal tissue.
34
Comparison between 5-hmC levels in control HCT116 cell and
DNMT1 null background also demonstrated reduced levels of
5-hmC due to a genetic knockout of the methyltransferase
gene, suggesting that a decrease in the level of the 5-mC
precursor may lead to less oxidative product.
18 There is one
area of concern when utilizing β-GT to measure global 5-hmC
levels, the presence of 5-hydroxymethyluracil (5-hmU) in the
tested genomic DNA samples. 5-hmU, which is also a substrate
Table 4. 5-hmC Content of Various Genomes and in Tumor and Normal Tissue Samples
a
genomic DNA sample
genome size
(bp)
%G C
content
fmol of 5-hmC/μgo f
DNA
total % 5-hmC in
genome
total % 5-hmC in
cytosines DNA
E14 cell line 2.65 × 109 42.0 9.0 ±0.9 0.30 0.71 mouse
3T3 cell line 3.6 ±0.2 0.12 0.28 mouse
mouse ESC (Tet1 control) 8.2 ±0.7 0.27 0.64 mouse
mouse ESC (Tet1 −/−) 6.6 ±0.0 0.22 0.52 mouse
mouse ESC, day 1 8.1 ± 0.1 0.27 0.63 mouse
mouse ESC, day 3 5.9 ±0.1 0.19 0.46 mouse
mouse ESC, day 5 8.1 ±0.4 0.27 0.64 mouse
mouse ESC, day 7 7.4 ±1.2 0.24 0.58 mouse
adult mouse spleen tissue 4.3 ±1.1 0.14 0.34 mouse
adult mouse brain tissue 27 ±0.5 0.90 2.1 mouse
adult mouse liver tissue 6.4 ±0.3 0.21 0.51 mouse
adult mouse kidney tissue 10 ±1.2 0.33 0.79 mouse
adult mouse heart tissue 10 ±2.2 0.33 0.79 mouse
adult mouse lung tissue 8.6 ±0.4 0.28 0.67 mouse
male rat 2.51 × 109 42.0 9.2 ±0.9 0.30 0.73 rat
female rat 7.1 ±1.1 0.23 0.56 rat
U87 cell line 3.08 × 109 41.0 5.8 ±2.4 0.19 0.47 human
293 cell line 7.3 ±3.0 0.24 0.59 human
HCT cell line 3.5 ±1.1 0.12 0.28 human
HCT cell line* (DNMT1 −/−) 2.2 ±0.0 0.07 0.17 human
HeLa cells 3.4 ±1.8 0.11 0.27 human
IMR90 cells 4.0 ± 2.6 0.13 0.32 human
human normal brain tissue 15 ±1.2 0.48 1.2 human
human normal lung tissue 4.6 ± 0.3 0.15 0.37 human
human normal breast tissue 4.7 ± 0.7 0.16 0.38 human
human normal colon tissue 6.1 ± 1.4 0.20 0.49 human
human normal liver tissue 6.8 ± 0.5 0.22 0.54 human
human tumor lung tissue 2.5 ± 0.2 0.08 0.20 human
human tumor breast tissue* 2.2 ± 0.1 0.07 0.18 human
human tumor colon tissue 2.7 ± 0.3 0.09 0.22 human
human tumor liver tissue 4.7 ± 0.4 0.15 0.37 human
human metastatic colon tissue 2.6 ±0.6 0.09 0.21 human
L. variegatus,* early gastrula 8.14 × 108 b 2.2 ±0.0 0.07 N/A sea urchin
L. variegatus,* late gastrula 2.2 ±0.0 0.07 N/A sea urchin
L. variegatus,* 36 h post
fertilization
3.3 ±0.4 0.11 N/A sea urchin
Arabidopsis* 1.25 × 108 2.2 ±0.0 0.07 N/A plant
soy bean* 1.15 × 109 2.2 ±0.0 0.07 N/A plant
rice* 3.90 × 108 2.2 ±0.1 0.07 N/A plant
bovine brain tissue 2.87 × 109 41.7 21 ±0.8 0.69 1.7 other mammals
male dog 2.38 × 109 41.0 5.8 ± 0.2 0.19 0.47 other mammals
chicken embryo 1.05 × 109 50.0 2.3 ±0.2 0.08 0.15 other mammals
rabbit liver tissue 2.60 × 109 4.1 ±0.6 0.13 N/A other mammals
Rhesus monkey heart 3.09 × 109 40.7 6.4 ±0.2 0.21 0.52 other mammals
COS cell line (Vervet monkey) 3.00 × 109 4.7 ±0.7 0.16 N/A other mammals
aGenomic 5-hmC content was determined by measuring the transfer of [3H]glucose to 5-hmC by recombinant β-GT in 1 μg of total genomic DNA.
Background measurements, which were obtained from β-GT glucosylation of 1 μg of synthetic poly(dI-dC) DNA containing no 5-hmC, were
subtracted from all values for genomic DNA samples. Genomic samples marked with an asterisk had ≤2 fmol of 5-hmC/μg of DNA and ≤0.07 total %
5-hmC in the genome. The total percentage of 5-hmC in cytosines was not calculated for genomes without percent GC determinations. Values of
genomic 5-hmC content for human matched normal and tumor tissues are bold and italicized.
bGenome of L. variegatus is estimated.
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35 arises from oxidation of the methyl group on
thymine in genomic DNA.
36 When utilizing β-GT for genomic
5-hmC measurements, the presence of 5-hmU can give false
measurements of elevated 5-hmC levels. This was not a
concern for our tested mammalian genomic DNA samples
because in these biological systems 5-hydroxymethyluracil-
DNA glycosylase (hmUDG) will glucosylate 5-hmU, leading to
its subsequent removal by nucleotide excision repair,
37 yet no
homologue for hmUDG has been discovered in either plants or
sea urchins; therefore, care needs to be taken when interpreting
the genomic 5-hmC levels with β-GT in lower organisms.
Our β-GT-based measurements of global 5-hmC levels
during ES cell differentiation were further validated for their
accuracy by comparing the data with HPLC-based measure-
ment of the genomic DNA that was hydrolyzed as
nucleobases.
8 Indeed, the patterns of 5-hmC changes were
very similar in both assay systems. A study by Szwagierczak
et al. used a comparable radioactive technique to measure total
5-hmC content, and even though they utilized different DNA
standards, they also identified a similar linear relationship
between the β-GT transfer of [3H]glucose and total 5-hmC
content (r = 0.9991).
18 However, in this earlier study, the
5-hmC levels were measured only in different mouse tissues at
different stages of development. We expanded upon this study
by establishing a more comprehensive measurement of 5-hmC
that was then applied to more than 40 different genomic
DNA samples, spanning 13 different prokaryotic and eukaryotic
species. In conclusion, β-GT-mediated global determination of
5-hmC levels is consistent with other analytical methods, and
because of the simplicity of glucose incorporation measure-
ment, smaller amounts of DNA can be used in the high-
throughput format.
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